Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

Recruiting now · Phase 4

Conditions studied: ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction

In brief

Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.

Key facts

Study ID

NCT07536802

Run by

National Institute of Cardiovascular Diseases, Pakistan

People needed

1148

Starts

2025-06-01

Expected to finish

2026-12-31

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients with acute STEMI undergoing primary PCI
• Patients of either sex, ≥18 years of age.

You may not qualify if…

• STEMI patients with cardiogenic shock at presentation
• Patients with heart block
• Allergy to adenosine
• Patients refuse to give consent for participation

Where it is running

• National Institute of Cardiovascular Diseases — Karachi, Sindh, Pakistan (enrolling)
• National Institute of Cardiovascular Diseases — Karachi, Sindh, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.